Aktis Oncology (AKTS) Metrics: History & Chart

Aktis Oncology, Inc.(AKTS)

Biotechnology · Boston, MA

$17.86-0.66 (-3.56%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.

Boston, MA

79 employees

www.aktisoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Matthew Roden

View full financials

Third-Party DCF Estimate (FMP)	$2.95
Price Gap vs Third-Party Estimate	-84.05%

7D Total Return	-4.29%
30D Total Return	-31.53%
YTD Total Return	N/A
1Y Total Return	N/A
3Y Total Return	N/A
5Y Total Return	N/A
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	N/A
2025	N/A
2024	N/A
2023	N/A
2022	N/A
2021	N/A

CAGR TTM	N/A
CAGR 3Y	N/A
CAGR 5Y	N/A
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

AKTS Valuation Metrics

AKTS Stock Price Metrics

AKTS Dividend Metrics

AKTS Growth Rate Metrics

AKTS Discounted Cash Flow Metrics

AKTS Returns By Period

AKTS Yearly Returns

AKTS Average Annual Returns By Period (CAGR)

AKTS Revenue Metrics

AKTS PE Ratio Metrics

AKTS PS Ratio Metrics

AKTS PB Ratio Metrics

AKTS Price to Free Cash Flow Ratio Metrics

AKTS Debt to Equity Ratio Metrics

AKTS PEG Ratio Metrics

AKTS FCF Yield

AKTS Earnings Yield

AKTS EBITDA Yield

AKTS OCF Yield

AKTS EV/EBIT Ratio Metrics

AKTS EV/EBITDA Ratio Metrics

AKTS EV/Assets Ratio Metrics

AKTS EV/Sales Ratio Metrics

AKTS Current Ratio Metrics

AKTS Quick Ratio Metrics

AKTS ROIC Metrics

AKTS Return on Assets Metrics

AKTS Return on Equity Metrics

AKTS Net Profit Margin Metrics

AKTS Gross Profit Margin Metrics

AKTS Tax Rate Metrics

PS Ratio	101.84
PS Ratio Avg TTM	127.87
PS Ratio Avg 3Y	127.87
Current VS TTM Avg	-20.36%
Current VS 3Y Avg	-20.36%
Current VS 5Y Avg	-20.36%

PB Ratio	2.11
PB Ratio Avg TTM	2.48
PB Ratio Avg 3Y	2.48
Current VS TTM Avg	-14.77%
Current VS 3Y Avg	-14.77%
Current VS 5Y Avg	-14.77%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.02
Debt/Equity Ratio Avg TTM	(0.03)
Debt/Equity Ratio Avg 3Y	(0.07)
Current VS TTM Avg	+175.65%
Current VS 3Y Avg	+133.04%
Current VS 5Y Avg	+133.04%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	1.71
Ev/Assets Ratio Avg TTM	2.33
Ev/Assets Ratio Avg 3Y	2.33
Current VS TTM Avg	-26.52%
Current VS 3Y Avg	-26.52%
Current VS 5Y Avg	-26.52%

Ev/Sales Ratio	94.76
Ev/Sales Ratio Avg TTM	120.79
Ev/Sales Ratio Avg 3Y	120.79
Current VS TTM Avg	-21.55%
Current VS 3Y Avg	-21.55%
Current VS 5Y Avg	-21.55%

Current Ratio	16.33
Current Ratio Avg TTM	13.11
Current Ratio Avg 3Y	14.50
Current VS TTM Avg	+24.50%
Current VS 3Y Avg	+12.62%
Current VS 5Y Avg	+12.62%

Quick Ratio	16.33
Quick Ratio Avg TTM	13.11
Quick Ratio Avg 3Y	14.50
Current VS TTM Avg	+24.50%
Current VS 3Y Avg	+12.62%
Current VS 5Y Avg	+12.62%

ROIC	(16.54%)
ROIC Avg 3Y	N/A
ROIC Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A

ROA	(13.12%)
ROA Avg TTM	(4.70%)
ROA Avg 3Y	(3.75%)
Current VS TTM Avg	-179.32%
Current VS 3Y Avg	-250.10%
Current VS 5Y Avg	-250.10%

ROE	(15.09%)
ROE Avg TTM	N/A
ROE Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	(727.04%)
Net Profit Margin Avg TTM	(768.65%)
Net Profit Margin Avg 3Y	(727.79%)
Current VS TTM Avg	+5.41%
Current VS 3Y Avg	+0.10%
Current VS 5Y Avg	+0.10%

Gross Profit Margin	100.00%
Gross Pft Margin Avg TTM	88.46%
Gross Pft Margin Avg 3Y	75.64%
Current VS TTM Avg	+13.05%
Current VS 3Y Avg	+32.21%
Current VS 5Y Avg	+32.21%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A